Personality trait dimensions and the pharmacological treatment of borderline personality disorder

Journal of Clinical Psychopharmacology

Volumn 29, Issue 5, 2009, Pages 461-467

  Saunders, Erika F H ^a,b   Silk, Kenneth R ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Borderline personality disorder; Personality traits; Pharmacotherapy; Psychiatry; Treatment

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ARIPIPRAZOLE; BENZODIAZEPINE; CARBAMAZEPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; OLANZAPINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TIOTIXENE; TOPIRAMATE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; VALPROATE SEMISODIUM;

ARTICLE; BIOLOGICAL TRAIT; BORDERLINE STATE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; HUMAN; IMPULSIVENESS; MENTAL INSTABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUICIDAL BEHAVIOR; SYSTEMATIC REVIEW;

BORDERLINE PERSONALITY DISORDER; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; PERSONALITY; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 70349659169     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181b2b9f3     Document Type: Article

References (46)

1. National Institute for Health and Clinical Excellence. Clinical Guideline 78. Borderline Personality Disorder: Treatment and Management. London, UK: National Collaborating Centre for Mental Health; 2009.
2. APA. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158:1-52.
3. Herpertz SC, Zanarini M, Schulz CS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry. 2007;8:212-244.
4. Soloff PH. Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin. 1998;62:195-214.
5. Binks CA, Fenton M, McCarthy L, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. January 2006:CD005653.
6. Nose M, Cipriani A, Biancosino B, et al. Efficacy of pharmacotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol. 2006;21: 345-353.
7. Duggan C, Huband N, Smailagic N, et al. The use of pharmacological treatments for people with personality disorder: a systematic review of randomized controlled trials. Pers and Men Health. 2008;2:119-170.
8. Clarkin JF, Widiger TA, Frances A, et al. Prototypic typology and the borderline personality disorder. J Abnorm Psychol. 1983;92: 263-275.
9. Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis I comorbidity of borderline personality disorder. Am J Psychiatry. 1998;155:1733-1739.
10. Zanarini MC, Frankenburg FR, Dubo ED, et al. Axis II comorbidity of borderline personality disorder. Compr Psychiatry. 1998;39: 296-302.
11. Siever LJ, Torgersen S, Gunderson JG, et al. The borderline diagnosis III: identifying endophenotypes for genetic studies. Biol Psychiatry. 2002;51:964-968.
12. Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry. 1991;148:1647-1658.
13. Bernstein DP, Iscan C, Maser J. Opinions of personality disorder experts regarding the DSM-IV personality disorders classification system. J Personal Disord. 2007;21:536-551.
14. Silk KR. Toward DSM-V: questions and controversies. In: Reich J, ed. Personality Disorders: Current Research and Treatments. New York, NY: Taylor & Francis; 2005:205-221.
15. Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104-109.
16. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 1997;54: 1081-1088.
17. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111-119.
18. de la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol. 1994;4:479-486.
19. Goldberg SC, Schulz SC, Schulz PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry. 1986;43:680-686.
20. Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry. 2005;162:621-624.
21. Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry. 2001;62:199-203.
22. Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26:61-66.
23. Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005;57:495-499.
24. Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006; 163:833-838.
25. Rinne T, van den BrinkW,Wouters L, et al. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry. 2002;159:2048-2054.
26. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15:23-29.
27. Schulz S, Zanarini MC, Detke H, et al. Olanzapine for the treatment of borderline personality disorder: a flexible-dose, 12-week, randomized, double-blind, placebo-controlled study. Presented at the 25th Biennial Congress of the Collegium Internationale Neuro-Psychopharmacologicum; July 9-13, 2006; Chicago, IL.
28. Simpson EB, Yen S, Costello E, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:379-385.
29. Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry. 2005;162:1221-1224.
30. Soloff PH, George A, Nathan S, et al. Amitriptyline and haloperidol in unstable and schizotypal borderline disorders. Psychopharmacol Bull. 1986;22:177-182.
31. Soloff PH, George A, Nathan RS, et al. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry. 1986;43:691-697.
32. Soloff PH, George A, Nathan RS, et al. Paradoxical effects of amitriptyline on borderline patients. Am J Psychiatry. 1986;143: 1603-1605.
33. Soloff PH, George A, Nathan RS, et al. Behavioral dyscontrol in borderline patients treated with amitriptyline. Psychopharmacol Bull. 1987;23:177-181.
34. Soloff PH, George A, Nathan S, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989;9:238-246.
35. Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50:377-385.
36. Cornelius JR, Soloff PH, Perel JM, et al. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 1993;150:1843-1848.
37. Cornelius JR, Soloff PH, George A, et al. Haloperidol vs. phenelzine in continuation therapy of borderline disorder. Psychopharmacol Bull. 1993;29:333-337.
38. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005;19:287-291.
39. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849-854.
40. Zanarini M, Schulz S, Detke H, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. Presented at the 25th Biennial Congress of the Collegium Internationale Neuro-Psychopharmacologicum; July 9-13, 2006; Chicago, IL.
41. Taylor MA, Devlin H, Schwiers M, et al. An international survey of pharmacotherapy in BPD. Abstract presented at the APA meeting, May 17-22, 2003; San Francisco, CA.
42. Coccaro EF, Kavoussi RJ, Hauger RL. Physiological responses to d-fenfluramine and ipsapirone challenge correlate with indices of aggression in males with personality disorder. Int Clin Psychopharmacol. 1995;10:177-179.
43. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972;26:57-63.
44. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119-142.
45. Sachs GS, Thase ME, OttoMW, et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003;53:1028-1042.
46. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull. 2003;29:15-31.